Abstract
HS-1793 is a novel derivative of resveratrol, a compound known for its numerous beneficial effects, including anticancer activity, anti-inflammatory response, antimicrobial, antiaging, anti-cardiovascular disease activity, neuroprotective activity, etc. Despite its wide and interesting properties, resveratrol suffers from a crucial flaw because it is low bioavailable. For this reason, many other derivatives were explored and among them, HS-1793 has caught the attention of researchers. HS-1793 is a synthetic derivative of resveratrol discovered in 2007 that has been shown to have anti-cancer and anti-inflammatory properties. In addition, the compound showed a positive profile in metabolic processes, with adequate pharmacokinetics and pharmacodynamics. This review highlights current research on HS-1793, evaluating in vitro and in vivo works and lays the foundation for novel explorative trials in human diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 2301-2311 |
| Number of pages | 11 |
| Journal | Future Medicinal Chemistry |
| Volume | 16 |
| Issue number | 21 |
| DOIs | |
| State | Published - 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- HS-1793
- anticancer
- bioavailability
- cell models
- preclinical
- resveratrol
Fingerprint
Dive into the research topics of 'Unveiling the potential of HS-1793: a review of its anticancer properties and therapeutic promise'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver